Business Description
BioNTech SE
ISIN : US09075V1026
Description
Financial Strength
9/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 68.57 | |||||
Equity-to-Asset | 0.85 | |||||
Debt-to-Equity | 0.01 | |||||
Debt-to-EBITDA | -0.7 | |||||
Piotroski F-Score | 2/9 | |||||
Altman Z-Score | 6.63 | |||||
Beneish M-Score | -3.5 | |||||
WACC vs ROIC |
Growth Rank
4/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 93.7 | |||||
3-Year EPS without NRI Growth Rate | 151.4 | |||||
3-Year Book Growth Rate | 137.8 | |||||
Future 3-5Y Total Revenue Growth Rate | -12.88 |
Momentum Rank
9/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 41.16 | |||||
9-Day RSI | 45.21 | |||||
14-Day RSI | 48.65 | |||||
6-1 Month Momentum % | 38.92 | |||||
12-1 Month Momentum % | 14.24 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 7.33 | |||||
Quick Ratio | 7.21 | |||||
Cash Ratio | 6.62 | |||||
Days Inventory | 267.1 | |||||
Days Sales Outstanding | 162.94 | |||||
Days Payable | 383.36 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | 0.5 | |||||
Shareholder Yield % | -0.14 |
Profitability Rank
4/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 84.34 | |||||
Operating Margin % | -23.16 | |||||
Net Margin % | -14.77 | |||||
FCF Margin % | 31.92 | |||||
ROE % | -2.31 | |||||
ROA % | -2.02 | |||||
ROIC % | -19.29 | |||||
ROC (Joel Greenblatt) % | -37.31 | |||||
ROCE % | -2.8 | |||||
Years of Profitability over Past 10-Year | 4 |
GF Value Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Price-to-Owner-Earnings | 16.56 | |||||
PS Ratio | 8.28 | |||||
PB Ratio | 1.29 | |||||
Price-to-Tangible-Book | 1.38 | |||||
Price-to-Free-Cash-Flow | 26.39 | |||||
Price-to-Operating-Cash-Flow | 16.75 | |||||
EV-to-EBIT | -14.68 | |||||
EV-to-Forward-EBIT | -6.2 | |||||
EV-to-EBITDA | -23.38 | |||||
EV-to-Forward-EBITDA | -7.2 | |||||
EV-to-Revenue | 2.72 | |||||
EV-to-Forward-Revenue | 3.64 | |||||
EV-to-FCF | 8.86 | |||||
Price-to-Projected-FCF | 0.44 | |||||
Price-to-Net-Current-Asset-Value | 1.62 | |||||
Price-to-Net-Cash | 1.84 | |||||
Earnings Yield (Greenblatt) % | -6.81 | |||||
FCF Yield % | 3.75 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
BioNTech SE Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil €) | 3,040.1 | ||
EPS (TTM) (€) | -1.97 | ||
Beta | 0.43 | ||
Volatility % | 43.19 | ||
14-Day RSI | 48.65 | ||
14-Day ATR (€) | 3.220204 | ||
20-Day SMA (€) | 112.315 | ||
12-1 Month Momentum % | 14.24 | ||
52-Week Range (€) | 69.6 - 116.1 | ||
Shares Outstanding (Mil) | 239.74 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 2 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
BioNTech SE Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
BioNTech SE Stock Events
Event | Date | Price(€) | ||
---|---|---|---|---|
No Event Data |
BioNTech SE Frequently Asked Questions
What is BioNTech SE(WBO:BNTX)'s stock price today?
When is next earnings date of BioNTech SE(WBO:BNTX)?
Does BioNTech SE(WBO:BNTX) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |